The role of alemtuzumab in the treatment of chronic lymphocytic leukemia (CLL) and the achievement of minimal residual disease negativity in relapsed/refractory CLL. Hematology Meeting Reports, [S. l.], v. 1, n. 2, 2009. DOI: 10.4081/hmr.v1i2.226. Disponível em: https://journals.pagepress.net/hmr/article/view/226. Acesso em: 19 apr. 2026.